朱朝晖，男，1969年生人。现任中国医学科学院北京协和医院医学科学研究中心常务副主任（主持工作），核医学科主任医师、党支部书记，北京协和医学院“协和学者”特聘教授，博士生导师。学术任职有中华医学会核医学分会常委/PET学组组长，中国医学装备协会核医学装备与技术专委会常委，中国医疗保健国际交流促进会神经内分泌肿瘤分会（CNETS）常委，中国生物物理学会分子影像分会委员，《协和医学》杂志副主编等。
    1995年毕业于中国协和医科大学医学八年制，获医学博士学位。迄今一直从事临床核医学诊疗工作。开展了10余种核医学分子影像新药物、新技术的国际首次临床转化。先后主持国家重点研发计划、国家自然科学基金等20余项课题研究。以第一和/或通讯作者发表国际高影响力期刊杂志文章60余篇，包括专业领域国际顶级刊物文章30余篇。参与20余部专业性著作编写。获省部级科技奖一等奖2项、二奖项6项等。

近三年以通讯作者发表的英文论著：
1. A single-arm, low-dose, prospective study of ¹⁷⁷Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2022 Nov 3: jnumed.122.264857.IF: 11.082
2. Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. Theranostics. 2022 Sep 6;12(15):6437-6445.IF: 11.600
3. A pilot study of ⁶⁸Ga-PSMA-617 PET/CT imaging and ¹⁷⁷Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma. EJNMMI Res. 2022 Aug 19;12(1):52.IF: 3.434
4. A prospective head-to-head comparison of ⁶⁸Ga-NOTA-3P-TATE-RGD and ⁶⁸Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4218-4227. IF: 10.057
5. Head-to-head comparison of [⁶⁸Ga]Ga-P16-093 and [⁶⁸Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1052-1062. IF: 10.057
6. Prognostic value of FDG PET/CT in patients with neuroendocrine carcinoma of the uterine cervix. Clin Nucl Med. 2021 Dec 1;46(12):971-976. IF: 10.782
7. Head-to-head comparison of ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4386-4395. IF: 10.057
8. Ga-68 EDTA aerosols in evaluation of inhaled-particle deposition and clearance of obstructive pulmonary diseases: A pilot prospective study compared with Galligas. Eur J Clin Invest. 2021 Dec;51(12):e13620. IF: 5.722
9. Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery. BioengTransl Med. 2020 Aug 31; 6(1):e10182. IF: 10.684
10. Peptide receptor radionuclide therapy of late-stage neuroendocrine tumor patients with multiple cycles of ¹⁷⁷Lu-DOTA-EB-TATE. J Nucl Med. 2021 Mar; 62(3): 386-392. IF: 11.600
11. ¹⁷⁷Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic Castration-resistant prostate cancer. J Nucl Med. 2020 Dec; 61(12): 1772-1778. IF: 11.600
12. Combined ⁶⁸Ga-NOTA-Evans blue lymphoscintigraphy and ⁶⁸Ga-NOTA-RM26 PET/CT evaluation of sentinel lymph node metastasis in breast cancer patients. Bioconjug Chem. 2020 Feb 19; 31(2): 396-403. IF: 6.069
13. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog ¹⁷⁷Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020 Apr; 47(4): 947-957. IF: 10.057